Natural killer (NK) cells are characterized by an efficient antitumor activity, and this activity has been exploited as the basis of cancer immunotherapy strategies. Interferon-a (IFN-a) is an important cytokine required for induction of the durable antitumor immune response and is an important stimulator of NK cells. In this study, to augment the efficiency of NK cell cytotoxicity to tumor cells, human IFN-a gene-modified natural killer cell line (NKL) (NKL-IFNa) cells, which could stably secrete IFN-a, were established. We investigated the natural cytotoxicity of NKL-IFNa cells against human hepatocarcinoma cells (HCCs) in vitro and in vivo. NKL-IFNa cells displayed a significantly stronger cytolytic activity against both human HCC cell lines and primary human hepatoma cancer cells compared with parental NKL cells. The increased cytolytic activity of NKL-IFNa cells was associated with the upregulation of cytotoxicity-related genes, such as perforin, granzyme B and Fas ligand, in the NK cells. Moreover, cytokines secreted by NKL-IFNa cells, such as tumor necrosis factor-a and IFN-g, induced increased expression of Fas on the target HCC cells, and resulted in increased susceptibility of the HCC cells to NK-mediated cytolysis. Encouragingly, NKL-IFNa cells could significantly inhibit HCC tumor growth in a xenograft model and prolonged the survival of tumor-bearing nude mice. These results suggest that IFN-a gene-modified NKL cells could be suitable for the future development of cell-based immunotherapeutic strategies for hepatocellular carcinoma.
INTRODUCTION
Natural killer (NK) cells are an important component of the innate immune system, and characterized by a strong cytolytic activity against various types of tumor cells and virus-infected cells via nonmajor histocompatibility complex (MHC)-restricted and non-T-cell receptor-restricted mechanisms. 1, 2 As an effector cell population, the intrinsic advantages of NK cells have led to the introduction of innovative strategies for cancer treatment. NK cell-based immunotherapy has been in development since the 1980s, and can potentially be implemented through the administration of cytokines or immunomodulatory drugs to activate endogenous NK cells, 3, 4 or the adoptive transfer of induced alloreactive NK cells developed from allogeneic stem cells, ex vivo expanded autologous NK cells 5 or donor-derived allogenic NK cells. 6 Owing to the difficulties of generating sufficient numbers of highly purified NK cells to meet clinical requirements, NK cell lines have become increasingly attractive for their unlimited ability to proliferate under good manufacturing practice conditions. 7 More importantly, gene modification, by which NK cell-acquired specificity and the cytolytic activity against tumor cells can be augmented, is more feasible in NK cell lines than primary NK cells. 8 Therefore, NK cell lines could be a useful tool for clinical adoptive immunotherapy.
The natural killer cell line (NKL) is a well-characterized malignant NK cell line, which was established from the peripheral blood of a patient with CD3 -CD16 þ CD56 þ large granular lymphocyte leukemia. The morphology of NKL cells resembles that of normal activated NK cells, with a CD16 þ CD56 dim phenotype and very similar natural killing, antibody-dependent cellular cytotoxicity and proliferative responses. 9 Of all NK cell lines, the NKL cell line had retained most of the original features of NK cells and could therefore potentially be used as a source of effector cells for adoptive immunotherapy. 10 NK cells not only produce a number of cytokines, through which they can suppress tumor cell proliferation, but they also respond to numerous cytokines, such as interleukin (IL)-1, IL-2, IL-12, IL-15, IL-18, IL-21 and type I interferon (IFN) a and b, which increase the cytolytic activity, cytokine production, proliferation and antitumor effects of NK cells. 11 Previously, we established IL-15 genemodified NKL and NK-92 cells with augmented antitumor ability. 12, 13 However, although the antitumor effects of NKL cells against HCC were enhanced by IL-15 gene modification, only some types of HCC cells were susceptible to NKL-IL-15 cells. 12 Since then, we have been trying to establish a novel genemodified NK cell line to act as a supplement for adaptive immunotherapy in patients with HCC.
IFN-a, a pleiotropic type I IFN, is one of the most important cytokines that activates NK cells. IFN-a is extensively used in the treatment of patients with hematological malignancies or certain solid tumors, such as melanoma and renal carcinoma.
14 IFN-a not only affects tumor cell function, for example, by downregulating oncogene expression and inducing tumor suppressor genes, but can also promote the differentiation and activity of host immune cells, including T cells, dendritic cells and NK cells, resulting in IFNa-induced antitumor immunity. 15, 16 IFN-a has also been widely used in the gene modification of dendritic cells for cancer immunotherapy. 17 On this basis, we used electroporation technology to modify genetically NKL cells with the human IFN-a gene (hIFNa) and 
RESULTS
Establishment of the hIFN-a gene-modified NKL cell line IFN-a, a type I IFN, exerts a variety of biological effects, including antitumor activity, and has been used in clinical oncology.
14 NKL cells are a typical immature NK cell line with a CD16 þ CD56 dim phenotype, which resemble activated NK cells. 9 In this study, we transferred the human INF-a (hIFN-a) gene into NKL cells using an electroporation method followed by Zeocin selection. As shown in Figure 1a , the levels of IFN-a mRNA in hIFN-a gene-modified NKL (NKL-IFNa) cells was significantly higher than the parental NKL cells. To confirm whether IFN-a gene-modified NKL cells secrete soluble IFN-a, an enzyme-linked immunosorbent assay (ELISA) was performed to quantify the levels of IFN-a secreted into the supernatant of NKL-IFNa cells and NKL cells transfected with the empty vector (NKL-vec cells). As shown in Figure 1b, Figure 2 , NKL-IFNa cells were significantly more cytotoxic to HepG2 and H7402 cells than NKL-vec cells at effector:target (E:T) ratios of 10:1 and 5:1. In addition, NKL-IFNa cells were also significantly more cytotoxic to HepG2.2.15 cells, a hepatitis B virus-positive (HBV þ ) HCC cell line, than NKL-vec cells. To further evaluate the cytotoxicity of NKL-IFNa cells, primary human hepatoma cancer cells isolated from three HCC patients were used as target cells. NKL-IFNa cells were significantly more cytotoxic to all three primary human hepatoma cancer cell lines than NKL-vec cells; the cytotoxicity of NKL-IFNa cells was 82.6 ± 5.1%, while the cytotoxicity of NKL-vec cells was 52.4±12.4% at the lowest E:T ratio (2.5:1). These data indicated that NKL-IFNa cells displayed an augmented cytotoxicity against HCC. In addition, as shown in Figure 2 , the difference between NKL-IFNa cell-and NKL-vec cell-mediated cytolysis against HCC hIFN-a gene modification of NKL cells W Jiang et al cells was reduced by increasing the E:T ratio, which suggests that a strategy of increasing the number of NK cells could be a useful therapeutic option.
To establish the effects of INF-a on NK cells themselves and/or the tumor cells, HepG2 cells were pretreated with or without 200 pg ml À 1 IFN-a for 6 h. IFN-a was removed by washing, and the cells were then exposed to parental NKL cells for the cytotoxicity assay. There was no significant difference between the cytotoxicity of NKL cells against IFN-a-treated and -untreated HepG2 cells at E:T ratios of 10:1 and 5:1 (Supplementary Figure S1) . These results indicate that the enhanced natural cytotoxicity of NKL-INFa cells against human HCC cells is mediated directly by the effects of IFNa on the NKL cells, rather than by IFN-a acting on the tumor cells. We observed that the sensitivity of HepG2 cells, which were treated with Fas siRNA for 24 h, to NKL-IFNa cell-mediated cytolysis was significantly inhibited, and NKL-IFNa cell-mediated cytolysis against Fas siRNA-treated HepG2 cells was similar to the levels as NKL-vec cell-mediated cytolysis at an E:T ratio of 5:1 (Figure 4d ), suggesting that elevated Fas expressed on HCC cells has a critical role in NKL-IFNa cell-mediated cytolysis.
IFN-a gene modification increases the activation of NKL cells

TNF-a and IFN-g secreted by NKL-IFNa cells induce the expression of Fas on HCC cells
It has been documented that expression of Fas can be induced on the surface of HCC cells by stimulation with TNF-a and IFN-g. 19 To investigate whether these cytokines contribute to the upregulated expression of Fas on HCC cells, NK cells were treated with TNF-aor/and an IFN-g-blocking mAb before coincubation with HepG2 cells. As shown in Figure 5a , blocking both TNF-a and IFN-g significantly decreased the expression of Fas on HepG2 cells, concomitant with a suppression of NK cell-mediated lysis against HepG2 cells (Figure 5b ). These data demonstrate that cytokines produced by IFN-a gene-modified NKL cells, such as TNF-a and IFN-g, are also involved in NKL-IFNa cell-mediated cytolysis, possibly by inducing increased expression of Fas on the target cells. Therefore, the application of NK cells in human cancer immunotherapy is gaining increasing attention, and treatments using NK cells have recently entered clinical trials. 21 Owing to their unlimited ability to proliferate under good manufacturing practice conditions, NK cell lines provide an attractive source of cells for NK cell-based cellular immunotherapy. 22 Most importantly, the antitumor activities of NK cell lines can be further enhanced by genetic engineering, to make the cells more cytotoxic or more easily expanded and maintained in vitro. 7 In previous work, several cytokine genes, including IL-2, IL-15 and stem cell factor (SCF), were adopted for gene modification to augment the activation of NK cells and increase their cytotoxicity towards tumor cells. 12, 13, 23, 24 However, the spectra of target cells, which are susceptible to cytolysis by different gene-modified NK cells, can vary. Therefore, it is necessary to research and develop various kinds of gene-modified NK cells for application in clinical cancer therapy.
As an important factor linking innate and adaptive immunity, IFN-a acts directly on T cells and NK cells to induce phenotypic activation, and prevent activation-induced cell death of cytotoxic T-lymphocytes. 25, 26 IFN-a, a pleiotropic cytokine, can also exert important effects on the differentiation and function of dendritic cells, 27, 28 and has been applied for gene modification of dendritic cells. 29, 30 In addition, IFN-a can directly inhibit the proliferation of tumor cells in vitro and in vivo.
14 Therefore, in this study, we selected hIFN-a for gene modification of the NKL cell line, and established hIFN-a gene-modified NKL cells, which retained many of the original phenotypic features of NK cells (Figure 1 One mechanism implicated in NK cell cytotoxicity is the release of cytoplasmic granules, such as perforin and granzymes, which lyse the target cells. Indeed, we observed that the expression of cytotoxicity-associated molecules, including TNF-a, granzyme B, perforin, IFN-g and FasL, was upregulated in IFN-a gene-modified NKL cells (Figure 3a Another pathway of NK cell-induced cytolytic activity is mediated by the surface TNF ligand family members, including FasL, TNF-a and TNF-related apoptosis-inducing ligand. These ligands interact with specific receptors on the target cell surface, and can induce tumor-cell apoptosis. However, activated NK cells can also secrete a number of effector cytokines, such as IFN-g, TNF-a, granulocyte-macrophage colony-stimulating factor, granulocyte-colony-stimulating factor and macrophage-colony-stimulating factor. [33] [34] [35] Indeed, we observed an increase in the expression of FasL by NKL-IFNa cells (Figure 3b ). To determine whether IFN-a gene modification could enhance the natural cytotoxicity of NKL cells and lead to increased apoptosis in HCC cells, the expression of apoptosis-associated genes was quantified in the target HCC cells. Fas was upregulated in HCC cells exposed to NKL-IFNa cells, and we observed that Fas has a critical role in NKL-IFNa cell-mediated lysis of HCC cells (Figure 4 ). In line with other publications, 36, 37 further investigation demonstrated that the cytokines TNF-a and IFN-g, which were produced by NKL-IFNa cells, induced the expression of Fas on the surface of the HCC cells. As shown in Figure 5 , the expression of Fas on HepG2 cells was significantly increased by coculture with NKL-IFNa cells; however, the expression of Fas on HCC cells in response to NKL-IFNa cells was suppressed by incubation with TNF-a-or IFN-g-blocking mAbs, which was concomitant with an attenuation of the susceptibility of HCC cells to NKL-IFNa cellinduced cytolysis.
Adoptive immunotherapy using NKL-IFNa cells could be applied in combination with other therapeutic strategies. For example, the androgen receptor has an important role in the growth of HCC and contributes significantly to the preferential development of HCC in men. 38 Combination therapy with the use of an androgen receptor-blocking agent could enhance the antitumor efficacy of NKL-IFNa cells in HCC patients.
Taken together, these findings demonstrate that IFN-a gene modification of NKL cells promoted the expression of granzyme B and perforin, which were responsible for enhanced NKL cell cytotoxicity. In addition, the IFN-a gene modification promoted the ability of NKL cells to induce HCC cell apoptosis, as NKL-IFNa cells induced the expression of Fas on the HCC cells. On the basis of these results, this study suggests that hIFN-a gene-modified NKL cells may represent a novel and potential immunotherapeutic strategy for HCC, which could complement the use of IL-15 gene-modified or other gene-modified NK cells.
MATERIALS AND METHODS
Cell culture and cell lines
The human HCC cell lines HepG2 and H7402 were conserved in our laboratory and cultured in RPMI-1640 medium (GIBCO/BRL, Grand Island, NY, USA) supplemented with 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin and 10% fetal bovine serum (FBS). HepG2.2.15 cells (serotype ayw, genotype D), derived from HepG2 cells by transfection with a plasmid carrying two head-to-tail copies of HBV genomic DNA, 39 were maintained in complete Dulbecco's modified Eagle's medium (GIBCO/BRL) supplemented with 10% FBS. NKL cells, a kind gift of Professor BQ Jin (Department of Immunology, Fourth Military Medical University, Xi'an, People's Republic of China), are conserved in our laboratory and were cultured in RPMI-1640 medium containing 10% FBS and 100 U ml À 1 IL-2. All cells were incubated at 37 1C in a 5% CO 2 atmosphere.
Patients and tumor tissue samples
Human primary HCC tissues were obtained from three HCC patients who underwent surgical resection at Shandong Provincial Hospital. None of these patients had received preoperative chemotherapy or radiotherapy. The HCC tissues were carefully washed with Hank's solution containing 2% FBS and 1% ethylenediaminetetraacetic acid, and then dissected into small pieces. Cell suspensions were obtained by mechanical dissociation, incubated in 0.25% trypsin at 37 1C for 20 min, and then the upper part of the cell suspension was carefully recovered and passed through a 70mm cell sieve. Primary human HCC cells were pelleted by centrifugation at 50 g for 10 min at 4 1C, resuspended at 60-70% confluence in RPMI-1640 containing 10% FBS and then used as target cells in the cytotoxicity assay. 0 -CGUAUGACACAUUGAUUAA-3 0 ; all siRNAs were purchased from Ribobio (Guangzhou, China).
Finally, the E/T cell mixtures were incubated for 6 h at 37 1C, 20 ml of 5 mg ml À 1 MTT solution was added and incubated for a further 4 h. The absorbance (A) values at 570 nm were determined using a microplate reader (Bio-Rad). Percentage (%) cytotoxicity was calculated as (1-(absorbance value of target plus effector cells À absorbance value of effector cells)/absorbance value of target cells) Â 100%.
RT-PCR and real-time RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) as described by the manufacturer, and cDNA was synthesized from 2 mg RNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA) and an oligo(dT) primer, as recommended by the manufacturer. The mRNA expression levels of IFN-a and the apoptosis-associated genes Bcl-2, Mcl-1 and Fas were determined by RT-PCR. Each PCR program consisted of 30 cycles of denaturation at 94 1C for 45 s, annealing at 58 1C for 45 s and extension at 72 1C for 1 min, followed by a final 10 min extension at 72 1C.
The mRNA expression levels of cytotoxicity-associated genes were determined by real-time RT-PCR using a TransStart SYBR qPCR Kit (Toyobo Co. Ltd, Osaka, Japan) using a MyiQ thermocycler (Bio-Rad). Each PCR reaction mixture (20 ml) contained 10 ml of 2 Â SYBR Green Master Mix and 7 ml of the forward and reverse primers (5 nM). The reactions were incubated for 10 min at 95 1C, followed by 45 cycles of 95 1C for 15 s, 60 1C for 15 s and 72 1C for 15 s. The expression levels of the target genes were normalized to GAPDH. The sequences of the PCR primers are listed in Table 1 .
Enzyme-linked immunosorbent assay
Approximately 1 Â 10 6 NKL-IFNa cells or NKL-vec cells were collected, washed three times with PBS, cultured in 10 ml RPMI-1640 medium for 24 or 48 h, and the supernatants were harvested. The levels of IFN-a in the cell culture supernatants were detected using an ELISA kit (R&D Systems), following the manufacturer's instructions. To induce secretion of IFN-g, the NKL-IFNa cells or NKL-vec cells were stimulated with or without PMA (5 mg ml À 1 ; Sigma, St Louis, MO, USA) and ionomycin (50 mg ml À 1 ; Sigma) for 24 and 48 h, and the levels of IFN-g were quantified using the ELISA.
Flow cytometry analysis
To detect Fas protein expression on the cell surface, the HCC cells were stained with a phycoerythrin (PE)/cy5-conjugated Fas antibody (R&D Systems) or isotype control antibody (eBioscience, San Diego, CA, USA) at 4 1C for 45 min. To detect FasL protein expression on the cell surface, NKL cells were stained with a PE-conjugated FasL antibody (eBioscience) or an isotype control antibody (eBioscience) at 4 1C for 45 min. For intracellular staining of TNF-a, perforin and granzyme B, NKL cells were treated with monensin (Sigma) for 4 h to inhibit the secretion of cytokines, harvested, washed once, fixed in 0.4% paraformaldehyde at 4 1C for 30 min, permeabilized in buffer containing 0.01% saponin (Sigma) and 0.09% NaN 3 (Sigma), followed by incubation for 1 h with PE-conjugated IFN-g, PE-conjugated TNF-a or fluorescein isothiocyanate-conjugated granzyme B antibodies (eBioscience). All stained cells were analyzed using a flow cytometer (FACScalibur; BD Biosciences, San Jose, CA, USA), and the data were processed with WinMDI 2.9 software (Scripps Research Institute, La Jolla, CA, USA).
Coculture assays
HepG2 cells and NKL-IFNa or NKL-vec cells were cocultured at a ratio of 1:1 using a 0.4-mm porous Transwell system (Corning Costar, Tewksbury, MA, USA) in 12-well plates for 24 h; complete RPMI-1640 medium served as the control.
Nude mouse xenograft assay
Female and male nude BALB/c mice (6 weeks-old) were obtained from the Shanghai Experimental Animal Center (Chinese Academy of Sciences, Shanghai, China), and housed under pathogen-free conditions. All handling and experimental procedures were conducted in accordance with experimental animal guidelines. To induce tumor growth, 5 Â 10 6 HepG2 cells (200 ml) were subcutaneously injected into the right flank of female or male mice. When the tumor volumes reached approximately 50 mm 3 (at 7 days after inoculation), the mice were randomly assigned to three groups with six mice in each group (PBS treatment control, NKL-vec treatment control and NKL-IFNa treatment group). After irradiation at 800 cGy (200 cGy min À 1 ), 5 Â 10 7 (2.5 Â 10 9 cells per kg) NKL-IFNa or NKLvec cells (200 ml) were harvested and intravenously injected into the mice on days 7 and 14 after tumor cell inoculation. Tumor growth was assessed every 5 days by measuring the tumor volume, calculated as V ¼ lw 2 /2, where l is the length and w is the width.
In addition, groups of six female mice were injected intraperitoneally with 5 Â 10 6 HepG2 cells (200 ml) to determine the survival of the xenograft mice. The mice were injected intravenously with PBS, 5 Â 10 7 irradiated 
